Technology and Innovation Focus Smart, Connected

Innovation is reshaping the needle-free injector landscape, as med-tech companies race to develop devices that are smarter, safer, and easier to use. 
Jet-based injectors remain dominant, offering reliable performance for high-viscosity biologics, but new spring-powered and digitally-assisted systems are gaining traction. Prefilled, single-use devices are now preferred in both clinical and home-care settings, capturing over 50% of the product share in 2024. 
The next frontier is connectivity. Emerging digital injectors can track dose timing, monitor adherence, and integrate with mobile health platforms—ideal for managing chronic conditions such as diabetes or hormone disorders. Companies are also experimenting with AI-driven pressure modulation to ensure optimal drug dispersion without tissue damage. 
Major players like Quinovare, PharmaJet, Crossject, and Portal Instruments are investing heavily in R&D. PharmaJet recently announced a new program developing needle-free self-injection pens for home use, marking a shift toward consumer-centric device design. 
As biologics, RNA therapeutics, and peptides become more common, the fusion of smart technology and needle-free delivery is setting a new industry standard—one that could ultimately make traditional syringes obsolete.